Regulatory Roundup for the Week of February 4, 2013

News
Article

The latest news from the pharmaceutical regulatory community.

FDA has releasedGuidance on Photosafety Evaluation of Pharmaceuticals S10, Step 2 Version (Nov. 13, 2012). This guidance recommends international standards for photosafety assessment, and harmonization of such assessments supporting human clinical trials and marketing authorization for pharmaceuticals.

In the effort to resolve the shortage of the cancer drug Doxil, FDA has approved the generic version of doxorubicin hydrochloride liposome injection, made by Sun Pharma Global FZE (Sun).

The European Medicines Agency and the Japanese Ministry of Health, Labour and Welfare (MHLW) have launched a public consultation on a joint reflection paper on the development of block-copolymer-micelle medicinal products.

The United States Pharmacopeia has announced the formation of three new Expert Committees for its Medicines Compendium (MC) and an expanded and enhanced website for the online-only compendium in response to the need for global public quality standards for medicines.

The United Kingdom’s Medicines and Healthcare products Regulatory Agency (MHRA) launched a public health campaign in partnership with pharmacy organizations to promote the need for the public reporting of suspected side effects from drugs through MHRA’s Yellow Card Scheme.

Recent Videos
Roger Viney from ICE Pharma discusses the quality and compliance issues surrounding the use of animal-derived ingredients in the bio/pharma industry.
Tore Bergsteiner from MAIN5 discusses the most pertinent and impactful bio/pharma industry trends from 2024.
Simon Wright from Almac Pharma Services chats about shifting demand for commercial manufacturing services and how service providers are adapting to meet demand.
Ian Lafferty from Upperton discusses the trends and challenges facing sterile manufacturing and how partnering with CDMOs can help innovators progress to the market.
Miguel Forte from ISCT and Kiji Therapeutics talks about the potential impact of a changing European political landscape.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.